Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements

This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.

Detalles Bibliográficos
Autores principales: Spetz, Joanne, Hailer, Laurie, Gay, Caryl, Tierney, Matthew, Schmidt, Laura, Phoenix, Bethany, Chapman, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099425/
https://www.ncbi.nlm.nih.gov/pubmed/35552728
http://dx.doi.org/10.1001/jamanetworkopen.2022.5996
_version_ 1784706602417258496
author Spetz, Joanne
Hailer, Laurie
Gay, Caryl
Tierney, Matthew
Schmidt, Laura
Phoenix, Bethany
Chapman, Susan
author_facet Spetz, Joanne
Hailer, Laurie
Gay, Caryl
Tierney, Matthew
Schmidt, Laura
Phoenix, Bethany
Chapman, Susan
author_sort Spetz, Joanne
collection PubMed
description This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.
format Online
Article
Text
id pubmed-9099425
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-90994252022-05-27 Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements Spetz, Joanne Hailer, Laurie Gay, Caryl Tierney, Matthew Schmidt, Laura Phoenix, Bethany Chapman, Susan JAMA Netw Open Research Letter This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic. American Medical Association 2022-05-12 /pmc/articles/PMC9099425/ /pubmed/35552728 http://dx.doi.org/10.1001/jamanetworkopen.2022.5996 Text en Copyright 2022 Spetz J et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Spetz, Joanne
Hailer, Laurie
Gay, Caryl
Tierney, Matthew
Schmidt, Laura
Phoenix, Bethany
Chapman, Susan
Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
title Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
title_full Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
title_fullStr Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
title_full_unstemmed Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
title_short Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
title_sort changes in us clinician waivers to prescribe buprenorphine management for opioid use disorder during the covid-19 pandemic and after relaxation of training requirements
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099425/
https://www.ncbi.nlm.nih.gov/pubmed/35552728
http://dx.doi.org/10.1001/jamanetworkopen.2022.5996
work_keys_str_mv AT spetzjoanne changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements
AT hailerlaurie changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements
AT gaycaryl changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements
AT tierneymatthew changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements
AT schmidtlaura changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements
AT phoenixbethany changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements
AT chapmansusan changesinusclinicianwaiverstoprescribebuprenorphinemanagementforopioidusedisorderduringthecovid19pandemicandafterrelaxationoftrainingrequirements

Ejemplares similares